SCHEMBL38429

SCHEMBL38429

C[C@H](N)c1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.63
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
HTR2B P41595 1/20 0.52
SLC6A2 P23975 4/20 0.49
SLC6A4 P31645 4/20 0.49
SLC6A3 Q01959 4/20 0.49
CYP2D6 P10635 3/20 0.49
CYP3A4 P08684 2/20 0.49
KCNH2 Q12809 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
AOC3 Q16853 2/20 0.49
CYP1A2 P05177 1/20 0.49
TSHR P16473 1/20 0.49
HIF1A Q16665 1/20 0.49
ATM Q13315 1/20 0.48
MMP9 P14780 1/20 0.46
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29463254 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL29350727 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL29471009 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL43789 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL307143 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL14019306 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL25434816 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
Hydrochloric Acid SCHEMBL6417289 0.98 UGT2B7 (0.61) UGT2B7HTR2AHTR2CHTR2BSLC6A2
Ammonia Solution, Strong SCHEMBL27895021 0.98 UGT2B7 (0.61) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL29254013 0.93 UGT2B7 (0.55) UGT2B7HTR2AHTR2CHTR2BSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4590663-A2 SYNTHESIS OF CYCLOPROPANE CARBOXYLIC ACIDS Takeda Pharmaceutical Company Limited (JP) 2025-07-30 EP claimed
US-12104106-B2 Compositions of chiral molecules and perovskite nanocrystals and methods of making the same ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2024-10-01 US claimed
CN-118084786-A Schiff base compound, preparation method and application thereof 安徽省东超科技有限公司 2024-05-28 CN claimed
WO-2024064214-A2 SYNTHESIS OF CYCLOPROPANE CARBOXYLIC ACIDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-03-28 WO claimed
CN-117005018-A Bromine-based two-dimensional chiral perovskite single-crystal nano-sheet and preparation method and application thereof 重庆邮电大学 2023-11-07 CN claimed
CN-114875472-B Organic-inorganic hybrid chiral perovskite helical structure micron sheet and preparation method and application thereof 河南大学 2023-11-03 CN claimed
EP-4247380-A1 METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS Aclaris Therapeutics, Inc. (US) 2023-09-27 EP claimed
US-11767309-B2 Methods of synthesizing substituted pyridinone-pyridinyl compounds ACLARIS THERAPEUTICS, INC. (US) 2023-09-26 US claimed
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US claimed
CN-116685322-A Method for synthesizing substituted pyridone-pyridyl compounds 阿克拉瑞斯治疗股份有限公司 2023-09-01 CN claimed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US claimed
US-20080090905-A1 Amine Salts Of (-)-2-((2-(4-Hydroxyphenyl)Ethyl)Thio)-3-(4-(2-(4-((Methylsulfonyl)Oxy)Phenoxy)Ethyl)Phenyl) Propanoic Acid SNAPE EVAN W 2008-04-17 US claimed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US claimed
CN-101080385-A Amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy)phenoxy)ethyl)phenyl)propanoic acid ASTRAZENECA AB (SE) 2007-11-28 CN claimed
EP-1838690-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY Devgen N.V. (BE) 2007-10-03 EP claimed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP claimed
WO-2007038277-A2 RESOLUTION OF ALPHA-(PHENOXY) PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES METABOLEX, INC. (US) 2007-04-05 WO claimed
US-20070073082-A1 Reacting enantiomers of 4-chloro- alpha -(3-trifluoromethylphenoxy)phenylacetic acid with (S)-(-)-1-(2-naphthyl)ethylamine to form an ammonium salt; separating the naphthylalkylammonium salt of the first enantiomer from the mixture; separating naphthylalkylamine METABOLEX, INC. (US) 2007-03-29 US claimed
WO-2006066879-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY DEVGEN N.V. (BE) 2006-06-29 WO claimed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090905-A1 Amine Salts Of (-)-2-((2-(4-Hydroxyphenyl)Ethyl)Thio)-3-(4-(2-(4-((Methylsulfonyl)Oxy)Phenoxy)Ethyl)Phenyl) Propanoic Acid GPR119, CPT1B, PNLIP UGT2B7 1607/4885HTR2A 396/4885HTR2C 1201/4885
US-11767309-B2 Methods of synthesizing substituted pyridinone-pyridinyl compounds PIR, PUM1, ZRANB2 UGT2B7 1988/4885HTR2A 1583/4885HTR2C 2767/4885
US-20070073082-A1 Reacting enantiomers of 4-chloro- alpha -(3-trifluoromethylphenoxy)phenylacetic acid with (S)-(-)-1-(2-naphthyl)ethylamine to form an ammonium salt; separating the naphthylalkylammonium salt of the first enantiomer from the mixture; separating naphthylalkylamine NAT1, SLC43A1, AGTR1 UGT2B7 1900/4885HTR2A 304/4885HTR2C 249/4885
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity KCNA4, HCN4, KCNN4 UGT2B7 780/4885HTR2A 2253/4885HTR2C 2278/4885
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family KCNA5, KCNA1, KCNJ2 UGT2B7 960/4885HTR2A 695/4885HTR2C 435/4885
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 UGT2B7 276/4885HTR2A 3991/4885HTR2C 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.